An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-07-25

AUTHORS

Fumihiko Kanai, Shuntaro Obi, Shigetoshi Fujiyama, Shuichiro Shiina, Hideyuki Tamai, Hitoshi Mochizuki, Yukihiro Koike, Jun Imamura, Takayoshi Yamaguchi, Isamu Saida, Osamu Yokosuka, Masao Omata

ABSTRACT

AimTamibarotene is a synthetic retinoid expected to inhibit tumor-cell proliferation and to induce apoptosis by selective interaction with retinoic acid receptor α/β. We conducted an open-label phase I/II study to determine the maximum tolerated dose (MTD) and recommended dose (RD), and to evaluate the pharmacokinetics, efficacy, and safety profiles for advanced hepatocellular carcinoma (HCC).MethodsPatients with histologically confirmed, measurable, unresectable HCC of Child-Pugh classification A or B and with no effective systemic or local therapies were eligible. In phase I, patients were assigned based on the 3 + 3 dose escalation criteria to receive tamibarotene at 8, 12, and 16 mg/day. The RD determined in phase I was employed for phase II. The planned sample size in phase II was 25, including the RD-treated patients in phase I.ResultsThirty-six patients were enrolled. No patients experienced dose-limiting toxicity (DLT) at 8 mg/day. However, two out of six patients experienced the DLTs at 12 mg/day: one experienced thrombosis in a limb vein and pulmonary artery, and the other experienced an increase of γ-GTP. The MTD and RD were determined as 12 and 8 mg/day, respectively. In phase II, one patient achieved partial response, and seven achieved stable disease. The disease control rate was 32 % (95 % CI: 15.0–53.5). The following drug-related serious adverse events were reported: thrombosis in a limb vein, pulmonary artery, and portal vein; interstitial lung disease; and vomiting.ConclusionsTamibarotene demonstrated the inhibition of tumor cell growth in advanced HCC with acceptable tolerance. More... »

PAGES

94-103

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12072-013-9459-7

DOI

http://dx.doi.org/10.1007/s12072-013-9459-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1045113608

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26202410


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba City, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba City, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kanai", 
        "givenName": "Fumihiko", 
        "id": "sg:person.01002073420.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002073420.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hepatology, Kyoundo Hospital, 1-8 Kandasurugadai, Chiyoda-ku, 101-0062, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Hepatology, Kyoundo Hospital, 1-8 Kandasurugadai, Chiyoda-ku, 101-0062, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Obi", 
        "givenName": "Shuntaro", 
        "id": "sg:person.01254432457.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254432457.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital, 1-17-27 Shinyashiki, 862-8655, Kumamoto City, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital, 1-17-27 Shinyashiki, 862-8655, Kumamoto City, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujiyama", 
        "givenName": "Shigetoshi", 
        "id": "sg:person.01115706741.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115706741.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, 113-8421, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.258269.2", 
          "name": [
            "Department of Gastroenterology, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, 113-8421, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shiina", 
        "givenName": "Shuichiro", 
        "id": "sg:person.0710636527.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710636527.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Second Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, 641-0012, Wakayama City, Wakayama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412857.d", 
          "name": [
            "Second Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, 641-0012, Wakayama City, Wakayama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tamai", 
        "givenName": "Hideyuki", 
        "id": "sg:person.07376146272.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07376146272.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu City, Yamanashi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417333.1", 
          "name": [
            "Department of Gastroenterology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu City, Yamanashi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mochizuki", 
        "givenName": "Hitoshi", 
        "id": "sg:person.01335140136.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335140136.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Kanto Central Hospital, 6-25-1 Kamiyouga, Setagaya-ku, 158-8531, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414990.1", 
          "name": [
            "Department of Gastroenterology, Kanto Central Hospital, 6-25-1 Kamiyouga, Setagaya-ku, 158-8531, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koike", 
        "givenName": "Yukihiro", 
        "id": "sg:person.01157314354.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157314354.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hepatology, Department of Internal Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, 113-8677, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415479.a", 
          "name": [
            "Division of Hepatology, Department of Internal Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, 113-8677, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Imamura", 
        "givenName": "Jun", 
        "id": "sg:person.01164435220.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164435220.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research 1, Zeria Pharmaceutical Co., Ltd, 10-11 Nihonbashi Kobuna-cho, Chuo-ku, 103-8351, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.510196.a", 
          "name": [
            "Clinical Research 1, Zeria Pharmaceutical Co., Ltd, 10-11 Nihonbashi Kobuna-cho, Chuo-ku, 103-8351, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamaguchi", 
        "givenName": "Takayoshi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research 1, Zeria Pharmaceutical Co., Ltd, 10-11 Nihonbashi Kobuna-cho, Chuo-ku, 103-8351, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.510196.a", 
          "name": [
            "Clinical Research 1, Zeria Pharmaceutical Co., Ltd, 10-11 Nihonbashi Kobuna-cho, Chuo-ku, 103-8351, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saida", 
        "givenName": "Isamu", 
        "id": "sg:person.01205143241.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205143241.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba City, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba City, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yokosuka", 
        "givenName": "Osamu", 
        "id": "sg:person.01270104553.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270104553.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yamanashi Prefectural Hospital Organization, 1-1-1 Fujimi, 400-8506, Kofu City, Yamanashi, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Yamanashi Prefectural Hospital Organization, 1-1-1 Fujimi, 400-8506, Kofu City, Yamanashi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Omata", 
        "givenName": "Masao", 
        "id": "sg:person.0775700471.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775700471.08"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-004-0837-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047246165", 
          "https://doi.org/10.1007/s00280-004-0837-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s004320050189", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014688055", 
          "https://doi.org/10.1007/s004320050189"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2403754", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011918258", 
          "https://doi.org/10.1038/sj.leu.2403754"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-07-25", 
    "datePublishedReg": "2013-07-25", 
    "description": "AimTamibarotene is a synthetic retinoid expected to inhibit tumor-cell proliferation and to induce apoptosis by selective interaction with retinoic acid receptor \u03b1/\u03b2. We conducted an open-label phase I/II study to determine the maximum tolerated dose (MTD) and recommended dose (RD), and to evaluate the pharmacokinetics, efficacy, and safety profiles for advanced hepatocellular carcinoma (HCC).MethodsPatients with histologically confirmed, measurable, unresectable HCC of Child-Pugh classification A or B and with no effective systemic or local therapies were eligible. In phase I, patients were assigned based on the 3\u00a0+\u00a03 dose escalation criteria to receive tamibarotene at 8, 12, and 16\u00a0mg/day. The RD determined in phase I was employed for phase II. The planned sample size in phase II was 25, including the RD-treated patients in phase I.ResultsThirty-six patients were enrolled. No patients experienced dose-limiting toxicity (DLT) at 8\u00a0mg/day. However, two out of six patients experienced the DLTs at 12\u00a0mg/day: one experienced thrombosis in a limb vein and pulmonary artery, and the other experienced an increase of \u03b3-GTP. The MTD and RD were determined as 12 and 8\u00a0mg/day, respectively. In phase II, one patient achieved partial response, and seven achieved stable disease. The disease control rate was 32\u00a0% (95\u00a0% CI: 15.0\u201353.5). The following drug-related serious adverse events were reported: thrombosis in a limb vein, pulmonary artery, and portal vein; interstitial lung disease; and vomiting.ConclusionsTamibarotene demonstrated the inhibition of tumor cell growth in advanced HCC with acceptable tolerance.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12072-013-9459-7", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1038556", 
        "issn": [
          "1936-0533", 
          "1936-0541"
        ], 
        "name": "Hepatology International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "dose-limiting toxicity", 
      "advanced hepatocellular carcinoma", 
      "open-label phase I/II study", 
      "phase I/II study", 
      "hepatocellular carcinoma", 
      "II study", 
      "pulmonary artery", 
      "limb veins", 
      "drug-related serious adverse events", 
      "Child-Pugh classification A", 
      "phase II", 
      "phase I", 
      "dose escalation criteria", 
      "disease control rate", 
      "serious adverse events", 
      "unresectable hepatocellular carcinoma", 
      "interstitial lung disease", 
      "tumor cell proliferation", 
      "tumor cell growth", 
      "stable disease", 
      "partial response", 
      "local therapy", 
      "adverse events", 
      "safety profile", 
      "lung disease", 
      "control rate", 
      "portal vein", 
      "\u03b3-GTP", 
      "escalation criteria", 
      "patients", 
      "synthetic retinoids", 
      "classification A", 
      "thrombosis", 
      "carcinoma", 
      "artery", 
      "vein", 
      "disease", 
      "dose", 
      "days", 
      "tamibarotene", 
      "cell growth", 
      "sample size", 
      "MethodsPatients", 
      "vomiting", 
      "pharmacokinetics", 
      "therapy", 
      "MTD", 
      "retinoids", 
      "efficacy", 
      "apoptosis", 
      "inhibition", 
      "proliferation", 
      "study", 
      "toxicity", 
      "RD", 
      "acceptable tolerance", 
      "response", 
      "criteria", 
      "rate", 
      "increase", 
      "events", 
      "tolerance", 
      "selective interaction", 
      "profile", 
      "growth", 
      "size", 
      "interaction", 
      "maximum"
    ], 
    "name": "An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma", 
    "pagination": "94-103", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1045113608"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12072-013-9459-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26202410"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12072-013-9459-7", 
      "https://app.dimensions.ai/details/publication/pub.1045113608"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_613.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12072-013-9459-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12072-013-9459-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12072-013-9459-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12072-013-9459-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12072-013-9459-7'


 

This table displays all metadata directly associated to this object as RDF triples.

243 TRIPLES      22 PREDICATES      97 URIs      86 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12072-013-9459-7 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N0ff9f923bb004df9a03e636dac22623a
4 schema:citation sg:pub.10.1007/s00280-004-0837-7
5 sg:pub.10.1007/s004320050189
6 sg:pub.10.1038/sj.leu.2403754
7 schema:datePublished 2013-07-25
8 schema:datePublishedReg 2013-07-25
9 schema:description AimTamibarotene is a synthetic retinoid expected to inhibit tumor-cell proliferation and to induce apoptosis by selective interaction with retinoic acid receptor α/β. We conducted an open-label phase I/II study to determine the maximum tolerated dose (MTD) and recommended dose (RD), and to evaluate the pharmacokinetics, efficacy, and safety profiles for advanced hepatocellular carcinoma (HCC).MethodsPatients with histologically confirmed, measurable, unresectable HCC of Child-Pugh classification A or B and with no effective systemic or local therapies were eligible. In phase I, patients were assigned based on the 3 + 3 dose escalation criteria to receive tamibarotene at 8, 12, and 16 mg/day. The RD determined in phase I was employed for phase II. The planned sample size in phase II was 25, including the RD-treated patients in phase I.ResultsThirty-six patients were enrolled. No patients experienced dose-limiting toxicity (DLT) at 8 mg/day. However, two out of six patients experienced the DLTs at 12 mg/day: one experienced thrombosis in a limb vein and pulmonary artery, and the other experienced an increase of γ-GTP. The MTD and RD were determined as 12 and 8 mg/day, respectively. In phase II, one patient achieved partial response, and seven achieved stable disease. The disease control rate was 32 % (95 % CI: 15.0–53.5). The following drug-related serious adverse events were reported: thrombosis in a limb vein, pulmonary artery, and portal vein; interstitial lung disease; and vomiting.ConclusionsTamibarotene demonstrated the inhibition of tumor cell growth in advanced HCC with acceptable tolerance.
10 schema:genre article
11 schema:inLanguage en
12 schema:isAccessibleForFree false
13 schema:isPartOf N64d712d6228642cb9634ff49cc525f65
14 N951fb6c09d944e2fa7c26b97e6c0f751
15 sg:journal.1038556
16 schema:keywords Child-Pugh classification A
17 II study
18 MTD
19 MethodsPatients
20 RD
21 acceptable tolerance
22 advanced hepatocellular carcinoma
23 adverse events
24 apoptosis
25 artery
26 carcinoma
27 cell growth
28 classification A
29 control rate
30 criteria
31 days
32 disease
33 disease control rate
34 dose
35 dose escalation criteria
36 dose-limiting toxicity
37 drug-related serious adverse events
38 efficacy
39 escalation criteria
40 events
41 growth
42 hepatocellular carcinoma
43 increase
44 inhibition
45 interaction
46 interstitial lung disease
47 limb veins
48 local therapy
49 lung disease
50 maximum
51 open-label phase I/II study
52 partial response
53 patients
54 pharmacokinetics
55 phase I
56 phase I/II study
57 phase II
58 portal vein
59 profile
60 proliferation
61 pulmonary artery
62 rate
63 response
64 retinoids
65 safety profile
66 sample size
67 selective interaction
68 serious adverse events
69 size
70 stable disease
71 study
72 synthetic retinoids
73 tamibarotene
74 therapy
75 thrombosis
76 tolerance
77 toxicity
78 tumor cell growth
79 tumor cell proliferation
80 unresectable hepatocellular carcinoma
81 vein
82 vomiting
83 γ-GTP
84 schema:name An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
85 schema:pagination 94-103
86 schema:productId N52a0a2d9cfcd4ab39e2cc910eaea70c9
87 N7ecc4abd42ab40538242a365be4ab55c
88 N7f0639861e264cc7895bb12725579f55
89 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045113608
90 https://doi.org/10.1007/s12072-013-9459-7
91 schema:sdDatePublished 2022-05-20T07:29
92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
93 schema:sdPublisher Na10d628b79524512a20d77a0c758e385
94 schema:url https://doi.org/10.1007/s12072-013-9459-7
95 sgo:license sg:explorer/license/
96 sgo:sdDataset articles
97 rdf:type schema:ScholarlyArticle
98 N03226e75b8b4481696802c5c53e10e76 rdf:first sg:person.01254432457.23
99 rdf:rest N047c6ae3eb704297b7bdb1ac93571ac5
100 N047c6ae3eb704297b7bdb1ac93571ac5 rdf:first sg:person.01115706741.37
101 rdf:rest Nebc3af7dceb74480b25c239a2d658e03
102 N0c3416286e7744f3b989b00646185239 rdf:first sg:person.01335140136.50
103 rdf:rest N485daca25d204674a3120a4067d040fb
104 N0ff9f923bb004df9a03e636dac22623a rdf:first sg:person.01002073420.18
105 rdf:rest N03226e75b8b4481696802c5c53e10e76
106 N485daca25d204674a3120a4067d040fb rdf:first sg:person.01157314354.15
107 rdf:rest N7fa6e198f8d040a7810ab0f91dff5f1f
108 N52a0a2d9cfcd4ab39e2cc910eaea70c9 schema:name pubmed_id
109 schema:value 26202410
110 rdf:type schema:PropertyValue
111 N5d6e7df82bb64fa78c3ae6c301b2f917 rdf:first sg:person.0775700471.08
112 rdf:rest rdf:nil
113 N64d712d6228642cb9634ff49cc525f65 schema:volumeNumber 8
114 rdf:type schema:PublicationVolume
115 N7ecc4abd42ab40538242a365be4ab55c schema:name doi
116 schema:value 10.1007/s12072-013-9459-7
117 rdf:type schema:PropertyValue
118 N7f0639861e264cc7895bb12725579f55 schema:name dimensions_id
119 schema:value pub.1045113608
120 rdf:type schema:PropertyValue
121 N7fa6e198f8d040a7810ab0f91dff5f1f rdf:first sg:person.01164435220.84
122 rdf:rest Nb41a2c6872d64e92a0d186c08fd97cf7
123 N951fb6c09d944e2fa7c26b97e6c0f751 schema:issueNumber 1
124 rdf:type schema:PublicationIssue
125 Na0c9f314cff8436f8faea729bce3756c schema:affiliation grid-institutes:grid.510196.a
126 schema:familyName Yamaguchi
127 schema:givenName Takayoshi
128 rdf:type schema:Person
129 Na10d628b79524512a20d77a0c758e385 schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 Na6b625a623c54766b51891b213e30942 rdf:first sg:person.01205143241.70
132 rdf:rest Nd4f0073409fd45c28292da3c02982c3c
133 Nb1ba08f19c0a41d1b2220b6b27f5daff rdf:first sg:person.07376146272.01
134 rdf:rest N0c3416286e7744f3b989b00646185239
135 Nb41a2c6872d64e92a0d186c08fd97cf7 rdf:first Na0c9f314cff8436f8faea729bce3756c
136 rdf:rest Na6b625a623c54766b51891b213e30942
137 Nd4f0073409fd45c28292da3c02982c3c rdf:first sg:person.01270104553.49
138 rdf:rest N5d6e7df82bb64fa78c3ae6c301b2f917
139 Nebc3af7dceb74480b25c239a2d658e03 rdf:first sg:person.0710636527.15
140 rdf:rest Nb1ba08f19c0a41d1b2220b6b27f5daff
141 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
142 schema:name Medical and Health Sciences
143 rdf:type schema:DefinedTerm
144 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
145 schema:name Clinical Sciences
146 rdf:type schema:DefinedTerm
147 sg:journal.1038556 schema:issn 1936-0533
148 1936-0541
149 schema:name Hepatology International
150 schema:publisher Springer Nature
151 rdf:type schema:Periodical
152 sg:person.01002073420.18 schema:affiliation grid-institutes:grid.136304.3
153 schema:familyName Kanai
154 schema:givenName Fumihiko
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002073420.18
156 rdf:type schema:Person
157 sg:person.01115706741.37 schema:affiliation grid-institutes:None
158 schema:familyName Fujiyama
159 schema:givenName Shigetoshi
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115706741.37
161 rdf:type schema:Person
162 sg:person.01157314354.15 schema:affiliation grid-institutes:grid.414990.1
163 schema:familyName Koike
164 schema:givenName Yukihiro
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157314354.15
166 rdf:type schema:Person
167 sg:person.01164435220.84 schema:affiliation grid-institutes:grid.415479.a
168 schema:familyName Imamura
169 schema:givenName Jun
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164435220.84
171 rdf:type schema:Person
172 sg:person.01205143241.70 schema:affiliation grid-institutes:grid.510196.a
173 schema:familyName Saida
174 schema:givenName Isamu
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205143241.70
176 rdf:type schema:Person
177 sg:person.01254432457.23 schema:affiliation grid-institutes:None
178 schema:familyName Obi
179 schema:givenName Shuntaro
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254432457.23
181 rdf:type schema:Person
182 sg:person.01270104553.49 schema:affiliation grid-institutes:grid.136304.3
183 schema:familyName Yokosuka
184 schema:givenName Osamu
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270104553.49
186 rdf:type schema:Person
187 sg:person.01335140136.50 schema:affiliation grid-institutes:grid.417333.1
188 schema:familyName Mochizuki
189 schema:givenName Hitoshi
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335140136.50
191 rdf:type schema:Person
192 sg:person.0710636527.15 schema:affiliation grid-institutes:grid.258269.2
193 schema:familyName Shiina
194 schema:givenName Shuichiro
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710636527.15
196 rdf:type schema:Person
197 sg:person.07376146272.01 schema:affiliation grid-institutes:grid.412857.d
198 schema:familyName Tamai
199 schema:givenName Hideyuki
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07376146272.01
201 rdf:type schema:Person
202 sg:person.0775700471.08 schema:affiliation grid-institutes:None
203 schema:familyName Omata
204 schema:givenName Masao
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775700471.08
206 rdf:type schema:Person
207 sg:pub.10.1007/s00280-004-0837-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047246165
208 https://doi.org/10.1007/s00280-004-0837-7
209 rdf:type schema:CreativeWork
210 sg:pub.10.1007/s004320050189 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014688055
211 https://doi.org/10.1007/s004320050189
212 rdf:type schema:CreativeWork
213 sg:pub.10.1038/sj.leu.2403754 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011918258
214 https://doi.org/10.1038/sj.leu.2403754
215 rdf:type schema:CreativeWork
216 grid-institutes:None schema:alternateName Department of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital, 1-17-27 Shinyashiki, 862-8655, Kumamoto City, Kumamoto, Japan
217 Department of Hepatology, Kyoundo Hospital, 1-8 Kandasurugadai, Chiyoda-ku, 101-0062, Tokyo, Japan
218 Yamanashi Prefectural Hospital Organization, 1-1-1 Fujimi, 400-8506, Kofu City, Yamanashi, Japan
219 schema:name Department of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital, 1-17-27 Shinyashiki, 862-8655, Kumamoto City, Kumamoto, Japan
220 Department of Hepatology, Kyoundo Hospital, 1-8 Kandasurugadai, Chiyoda-ku, 101-0062, Tokyo, Japan
221 Yamanashi Prefectural Hospital Organization, 1-1-1 Fujimi, 400-8506, Kofu City, Yamanashi, Japan
222 rdf:type schema:Organization
223 grid-institutes:grid.136304.3 schema:alternateName Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba City, Chiba, Japan
224 schema:name Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba City, Chiba, Japan
225 rdf:type schema:Organization
226 grid-institutes:grid.258269.2 schema:alternateName Department of Gastroenterology, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, 113-8421, Tokyo, Japan
227 schema:name Department of Gastroenterology, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, 113-8421, Tokyo, Japan
228 rdf:type schema:Organization
229 grid-institutes:grid.412857.d schema:alternateName Second Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, 641-0012, Wakayama City, Wakayama, Japan
230 schema:name Second Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, 641-0012, Wakayama City, Wakayama, Japan
231 rdf:type schema:Organization
232 grid-institutes:grid.414990.1 schema:alternateName Department of Gastroenterology, Kanto Central Hospital, 6-25-1 Kamiyouga, Setagaya-ku, 158-8531, Tokyo, Japan
233 schema:name Department of Gastroenterology, Kanto Central Hospital, 6-25-1 Kamiyouga, Setagaya-ku, 158-8531, Tokyo, Japan
234 rdf:type schema:Organization
235 grid-institutes:grid.415479.a schema:alternateName Division of Hepatology, Department of Internal Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, 113-8677, Tokyo, Japan
236 schema:name Division of Hepatology, Department of Internal Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, 113-8677, Tokyo, Japan
237 rdf:type schema:Organization
238 grid-institutes:grid.417333.1 schema:alternateName Department of Gastroenterology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu City, Yamanashi, Japan
239 schema:name Department of Gastroenterology, Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, 400-8506, Kofu City, Yamanashi, Japan
240 rdf:type schema:Organization
241 grid-institutes:grid.510196.a schema:alternateName Clinical Research 1, Zeria Pharmaceutical Co., Ltd, 10-11 Nihonbashi Kobuna-cho, Chuo-ku, 103-8351, Tokyo, Japan
242 schema:name Clinical Research 1, Zeria Pharmaceutical Co., Ltd, 10-11 Nihonbashi Kobuna-cho, Chuo-ku, 103-8351, Tokyo, Japan
243 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...